Literature DB >> 11479678

Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus.

D C Hughes1.   

Abstract

The vascular endothelial growth factor receptor 3 (VEGFR-3/FLT4) is a receptor tyrosine kinase that regulates angiogenesis and vasculogenesis in response to the binding of the ligands VEGF-C and VEGF-D. Mutations in VEGFR-3 have been identified in patients with primary lymphoedema. It has been noted previously that whilst in the mouse there is only a single Vegfr-3 transcript, in humans there are two transcripts of 5.8 and 4.5 kb, of which the shorter encodes a protein that lacks the C-terminal 65 amino acids. These two isoforms also differ in their biological activity. Analysis of the human VEGFR-3 cDNA and genomic sequence reveals that these two isoforms arise by alternative splicing of the terminal exons. The shorter transcript is generated by splicing into the long terminal repeat of a human endogenous retrovirus located between the last two exons, thus explaining the lack of the shorter transcript in the mouse. The retention of the retroviral sequences in the FLT4 locus suggests that this retrotransposition event has contributed significant additional function to this gene. This provides support for a role for integrated retroviruses in modulating gene activity and participating in evolutionary processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479678     DOI: 10.1007/s002390010195

Source DB:  PubMed          Journal:  J Mol Evol        ISSN: 0022-2844            Impact factor:   2.395


  13 in total

1.  Murine endogenous retroviruses and their transcriptional potentials.

Authors:  Jerry Boonyaratanakornkit; Alex Chew; Dewey D Y Ryu; David G Greenhalgh; Kiho Cho
Journal:  Mamm Genome       Date:  2004-11       Impact factor: 2.957

Review 2.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 3.  Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer.

Authors:  A D Karatzanis; E Koudounarakis; I Papadakis; G Velegrakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-21       Impact factor: 2.503

Review 4.  Retroelements and their impact on genome evolution and functioning.

Authors:  Elena Gogvadze; Anton Buzdin
Journal:  Cell Mol Life Sci       Date:  2009-08-02       Impact factor: 9.261

5.  Novel variants of human SCaMC-3, an isoform of the ATP-Mg/P(i) mitochondrial carrier, generated by alternative splicing from 3'-flanking transposable elements.

Authors:  Araceli Del Arco
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

6.  Exploring the effects of immunity and life history on the dynamics of an endogenous retrovirus.

Authors:  R K Kanda; M Tristem; T Coulson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-08-12       Impact factor: 6.237

7.  Lymphangiogenesis and lymphatic metastasis in breast cancer.

Authors:  Sophia Ran; Lisa Volk; Kelly Hall; Michael J Flister
Journal:  Pathophysiology       Date:  2009-12-24

Review 8.  The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases.

Authors:  Richard M Monaghan; Donna J Page; Pia Ostergaard; Bernard D Keavney
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

9.  Detecting host factors involved in virus infection by observing the clustering of infected cells in siRNA screening images.

Authors:  Apichat Suratanee; Ilka Rebhan; Petr Matula; Anil Kumar; Lars Kaderali; Karl Rohr; Ralf Bartenschlager; Roland Eils; Rainer König
Journal:  Bioinformatics       Date:  2010-09-15       Impact factor: 6.937

Review 10.  The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.

Authors:  Gina A Smith; Gareth W Fearnley; Darren C Tomlinson; Michael A Harrison; Sreenivasan Ponnambalam
Journal:  Biosci Rep       Date:  2015-08-18       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.